AmerisourceBergen Drug Corporation
AmerisourceBergen Drug Corporation, commonly referred to as AmerisourceBergen, is a leading global healthcare solutions provider headquartered in the United States. Founded in 2001, the company has established itself as a key player in the pharmaceutical distribution industry, serving healthcare providers across North America and beyond. Specialising in pharmaceutical distribution, AmerisourceBergen offers a comprehensive range of services, including supply chain management, logistics, and consulting. The company is renowned for its commitment to improving patient access to medications and enhancing the efficiency of healthcare delivery. With a strong market position, AmerisourceBergen has achieved significant milestones, including strategic partnerships and innovative solutions that set it apart in the competitive landscape.
DitchCarbon Score
How does AmerisourceBergen Drug Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AmerisourceBergen Drug Corporation's score of 33 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AmerisourceBergen Drug Corporation's reported carbon emissions
In 2021, AmerisourceBergen Drug Corporation reported significant carbon emissions, totalling approximately 112,936,750 kg CO2e for Scope 1 and 96,472,630 kg CO2e for Scope 2 on a global scale. In the US specifically, the company emitted about 21,309,311 kg CO2e for Scope 1 and 66,627,361 kg CO2e for Scope 2. Notably, the company has not disclosed any Scope 3 emissions data for the US region. The emissions data indicates a commitment to transparency, as AmerisourceBergen has provided detailed disclosures across multiple scopes. However, there are currently no specific reduction targets or initiatives outlined in their climate commitments. This lack of defined reduction strategies suggests that while the company is actively monitoring its emissions, it may need to establish clearer goals to enhance its climate action efforts. Overall, AmerisourceBergen's emissions profile reflects the broader industry context, where pharmaceutical companies are increasingly scrutinised for their environmental impact and are expected to adopt more robust climate strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Scope 1 | 109,727,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 105,581,090 | 00,000,000 | 00,000,000 |
| Scope 3 | 19,532,581,490 | - | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AmerisourceBergen Drug Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
